Posttransplantation lymphoproliferative disorder in lung transplant recipients: A 15-year single institution experience

Transplantation

Volumn 96, Issue 7, 2013, Pages 657-663

  Muchtar, Eli ^a,b   Kramer, Mordechai R ^a,b   Vidal, Liat ^a,b   Ram, Ron ^a,b   Gurion, Ronit ^a,b   Rosenblat, Yivgenia ^a,b   Bakal, Ilana ^a,b   Shpilberg, Ofer ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

EBV; Late onset; Lung transplantation; PTLD

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHRONIC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; OUTCOME ASSESSMENT; PLASMABLASTIC LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; T CELL LYMPHOMA; THORAX RADIOGRAPHY; WEIGHT REDUCTION;

ADOLESCENT; ADULT; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; ISRAEL; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885418457     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829b0718     Document Type: Article

References (33)

1. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155.
2. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
3. Aris RM, Maia DM, Neuringer IP, et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 1712.
4. Elidemir O, Kancherla BS, Schecter MG, et al. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring. Pediatr Transplant 2009; 13: 606.
5. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15: 647.
6. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242.
7. Lucioni M, Capello D, Riboni R, et al. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution. Transplantation 2006; 82: 1013.
8. Wudhikarn K, Holman CJ, Linan M, et al. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota. Clin Transplant 2011; 25: 705.
9. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827.
10. Bakker NA, van Imhoff GW, Verschuuren EA, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327.
11. Blaes AH, Morrison VA. Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol 2010; 3: 35.
12. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244.
13. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 2011; 305: 163.
14. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park) 2010; 24: 936.
15. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894.
16. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttrans-plant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116: 1273.
17. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21: 547.
18. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165.
19. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lympho-proliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877.
20. Einollahi B, Lessan-Pezeshki M, Nourbala MH, et al. Post-transplant lymphoproliferative disorders in kidney transplant recipients: an Iranian multicenter experience. Iran J Kidney Dis 2008; 2: 227.
21. Kremer BE, Reshef R, Misleh JG, et al. Post-transplant lympho-proliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant 2012; 31: 296.
22. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200.
23. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol 1994; 5: 29.
24. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24: 671.
25. Hayashi RJ, Kraus MD, Patel AL, et al. Posttransplant lympho-proliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001; 23: 14.
26. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immu-nosuppression as initial therapy for posttransplantation lympho-proliferative disorder (bigstar). Am J Transplant 2011; 11: 336.
27. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immuno-suppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076.
28. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorderin adult solid organ transplant recipientsV BCSH and BTS guidelines. Br J Haematol 2010; 149: 693.
29. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23: 6481.
30. Trappe RU, Dierickx D, Reinke P, et al. Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST). ASCO Meet Abstr 2012; 30: 8030.
31. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166: 440.
32. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
33. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257.